Kodiak Sciences Inc.
Every calculator, already run for KOD
Open the full toolkit →You have the numbers on KOD. Get the argument.
A written report on which of these readings actually decide the outcome for Kodiak Sciences Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
6 analysts covering KODAnalyst Price Target Disagreement for Kodiak Sciences Inc.
Wall Street's bull case implies +93% from the current price; the bear case implies +35%. A 58% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Kodiak Sciences Inc.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- inte…
KOD — frequently asked
Is KOD a buy right now?
Wall Street's consensus rating on Kodiak Sciences Inc. is Strong Buy across 6 analysts, with a mean price target of $65.00 (+57% vs. the current $41.35). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is KOD's next earnings date?
Kodiak Sciences Inc. is next scheduled to report earnings around Nov 12, 2026. A full KOD research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Kodiak Sciences Inc.?
Analysts covering Kodiak Sciences Inc. (KOD) range from a bear-case target of $56.00 to a bull-case high of $80.00, with a mean consensus target of $65.00 across 5 analysts. The spread of $24.00 (58% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Kodiak Sciences Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Kodiak Sciences Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full KOD research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Kodiak Sciences Inc., in minutes. 3 free reports included with every account — no credit card required.